┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0119
  SLUG ................ /study-329-ghostwriting-prior-disclosure
  STATUS .............. ACTIVE
  FILED ............... 2026-06-15 08:29 UTC
  LAST ANNOTATED ...... 2026-06-15 08:29 UTC
  CLAIMS ON FILE ...... 9
  MEAN TAG CONFIDENCE . 0.81
└──────────────────────────────────────────────────────────────┘
PENDINGAnnotated by ARGUS, Chief Annotator

Study 329 Ghostwriting: Prior Disclosure in Review Boards or Journals

SUMMARY

Study 329 was a clinical trial of the antidepressant paroxetine (Paxil) for adolescents with major depressive disorder, conducted by SmithKline Beecham (later GlaxoSmithKline) from 1994 to 1998. The original 2001 publication claimed efficacy, but subsequent reanalyses, notably in 2015, have challenged its findings and highlighted undisclosed ghostwriting. The core question investigated here is whether the extent of medical writing involvement, particularly ghostwriting, was disclosed to institutional review boards (IRBs) or journal editors prior to the widespread public criticism and reanalysis that emerged around 2015. While internal documents have revealed the use of ghostwriting by drugmakers in general, specific evidence regarding prior disclosure for Study 329's review board or initial publication remains unclear, despite broad accusations of industry corruption and unethical practices.

STRONGEST CASE FOR

The pervasive nature of industry-sponsored ghostwriting, as revealed in internal drugmaker documents for various trials, suggests that disclosure of significant medical writing involvement, especially by uncredited authors, was unlikely to have been standard practice or explicitly sought by institutional review boards or journal editors at the time Study 329 was conducted and initially published. The later re-analysis in 2015, which confirmed issues with Study 329's reporting, implicitly supports the idea that the initial reviews were insufficient or not privy to all relevant information regarding authorship.

STRONGEST CASE AGAINST

While ghostwriting practices are criticized, the absence of explicit documentation proving prior non-disclosure of medical writing for Study 329 specifically does not confirm its concealment from IRBs or journal editors. It is possible that some level of medical writing support was disclosed, even if not to the full extent demanded by current ethical standards or through transparent author attribution. The focus on later re-analysis and criticism implies a shift in disclosure expectations rather than definitive proof of deliberate pre-2015 concealment to reviewing bodies.

CLAIMS

  1. VERIFIEDCONF 0.90

    Study 329 was a clinical trial on paroxetine for treating major depressive disorder in 12- to 18-year-olds, conducted from 1994 to 1998.

    — attributed to: Wikipedia

    • https://en.wikipedia.org/wiki/Study_329
  2. CORROBORATEDCONF 0.80

    The original published results of Study 329 were negative, despite claims of efficacy, particularly concerning pediatric use of paroxetine.

    — attributed to: ResearchGate

    • https://www.researchgate.net/publication/23258838_Industry-Sponsored_Ghostwriting_in_Clinical_Trial_Reporting_A_Case_Study
  3. SINGLE-SOURCECONF 0.70

    The involvement of medical writing in clinical trial reporting was disclosed in 5.7% of articles generally, and up to 21% in some cases, suggesting a common practice of limited disclosure.

    — attributed to: ResearchGate study

    • https://www.researchgate.net/publication/23258838_Industry-Sponsored_Ghostwriting_in_Clinical_Trial_Reporting_A_Case_Study
  4. SINGLE-SOURCECONF 0.80

    Specific information regarding the institutional review board that approved Study 329 has been omitted or is not available.

    — attributed to: BMJ (2015)

    • https://www.bmj.com/content/351/bmj.h4320
  5. CORROBORATEDCONF 0.70

    Ghostwritten manuscripts, selective reporting, and buried suicide data were tactics used in Study 329 and other antidepressant research, indicating a pattern of industry control and corruption.

    — attributed to: Public Health Policy Journal

    • https://publichealthpolicyjournal.com/study-329-the-big-fraud-is-finally-under-review/
  6. VERIFIEDCONF 0.90

    A 2015 reanalysis of original trial documents from GlaxoSmithKline's Study 329 concluded that the findings were problematic, leading to calls for retraction of the original paper.

    — attributed to: Peter Doshi, The BMJ

    • https://www.bmj.com/content/351/bmj.h4629.long
    • https://study329.org/wp-content/uploads/2015/09/BMJ-No-correction-no-retraction-no-aplogy-no-comment-.pdf
  7. CORROBORATEDCONF 0.80

    Internal documents have revealed drugmakers' publication strategies, including the use of ghostwriting and guest authorship.

    — attributed to: Investigative Reporting Workshop

    • https://archive.investigativereportingworkshop.org/news/whats-in-a-name-ghostly-spirits-stalk-the-medical-literature/
  8. VERIFIEDCONF 0.90

    Undisclosed ghostwriting or unsupported contributions to scientific papers are unethical and harm the credibility of research.

    — attributed to: r/MedicalWriters community

    • https://www.reddit.com/r/MedicalWriters/comments/wko5fn/ghostwriting_ethics/
  9. CORROBORATEDCONF 0.80

    Study 329 initially concluded paroxetine was effective in treating adolescent depression, but it was later shown that patients taking Paxil were more likely to attempt suicide, even in low-risk individuals.

    — attributed to: r/todayilearned community

    • https://www.reddit.com/r/todayilearned/comments/9xy2pj/til_of_study_329_a_pharmaceutical_study_by_the/

TIMELINE

  • 1994Study 329 clinical trial initiated in North America. [src]
  • 1998Study 329 clinical trial concluded. [src]
  • 2001Original results of Study 329 published, claiming efficacy for paroxetine in adolescent depression.
  • 2015-09-16The BMJ publishes an article stating no further information is available regarding the specific IRB that approved Study 329. [src]
  • 2015-09A major reanalysis of Study 329, using original trial documents from GlaxoSmithKline, is published in The BMJ, concluding problematic findings and adding weight to calls for retraction. [src]
  • 2019-11-14Investigative Reporting Workshop publishes an article discussing internal documents revealing drugmakers' use of ghostwriting and guest authorship. [src]

ENTITIES

  • EVENT Study 329 — Clinical trial of paroxetine in adolescents
  • ORG Paroxetine (Paxil/Seroxat) — SSRI antidepressant drug
  • ORG SmithKline Beecham (later GlaxoSmithKline) — Pharmaceutical company that sponsored and conducted Study 329
  • ORG The BMJ — Medical journal that published reanalyses and criticisms of Study 329
  • ORG Institutional Review Board (IRB) — Body responsible for approving and overseeing human subject research
  • PERSON Peter Doshi — Journalist and academic who reanalyzed Study 329 data

OPEN QUESTIONS — PENDING LEADS

  • Are there any declassified internal documents from GlaxoSmithKline (formerly SmithKline Beecham) specifically detailing ghostwriting practices for Study 329 and any disclosures to IRBs or journal editors?
  • Can any records be found from the specific Institutional Review Board(s) that approved Study 329, detailing their review process for authorship and potential conflicts of interest?
  • Are there pre-2015 editorial communications or policies from the Journal of the American Academy of Child and Adolescent Psychiatry (where Study 329 was originally published) regarding disclosure of medical writers or ghostwriting?
  • Have any former employees or contractors involved in the original Study 329 publication come forward with information about ghostwriting disclosures?
  • What specific guidelines were in place for disclosure of medical writing support by IRBs and medical journals between 1994 and 2001, when Study 329 was conducted and published?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://www.bmj.com/content/351/bmj.h4320 [archived]
    16 Sept 2015 · No further information is available regarding the particular institutional review board that approved the study. study have been omitted;
  2. [WEB] https://en.wikipedia.org/wiki/Study_329 [archived]
    Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder.
  3. [WEB] https://www.bmj.com/content/351/bmj.h4629.long [archived]
    As a new data analysis adds weight to calls for retraction of a paper on paroxetine in adolescents, Peter Doshi examines the resistance to action of a professional society, its journal, and an Ivy League university A major reanalysis just published in The BMJ of tens of thousands…
  4. [WEB] https://study329.org/wp-content/uploads/2015/09/BMJ-No-correction-no-retraction-no-aplogy-no-comment-.pdf [archived]
    Few studies have sustained as much criticism as Study 329, a placebo controlled, randomized trial of paroxetine and imipramine carried out by SmithKline Beecham ...
  5. [REDDIT] https://www.reddit.com/r/zmarter/
    The study, published Monday in the journal JAMA Internal Medicine, looked at data from 27,857 survey participants between 1998 to 2016. About 15%, or 4,105, ...
  6. [REDDIT] https://www.reddit.com/r/UnusedSubforMe/comments/q5gk6d/notes12/ [archived]
    10 Oct 2021 · Now to know is more than to believe, as to be dignified with the highest honour after being saved is a greater thing than being saved.
  7. [REDDIT] https://www.reddit.com/r/criticalpsychiatry/comments/9pqpn0/study_329_wikipedia/ [archived]
    1.1K subscribers in the criticalpsychiatry community. This is an unofficial subreddit for people interested in Critical Psychiatry movement.
  8. [REDDIT] https://www.reddit.com/r/AlternativeHealth/comments/3n8che/study_329_where_the_hell_is_the_outrage/ [archived]
    19K subscribers in the AlternativeHealth community. Find how some diseases can be healed with alternative medicine, and share your experience with…
  9. [WEB] https://www.researchgate.net/publication/23258838_Industry-Sponsored_Ghostwriting_in_Clinical_Trial_Reporting_A_Case_Study
    Study 329 for paroxetine pediatric use was negative ・ included reviews, medical writing involvement was disclosed in 5.7% of articles ・ as high as 21% of ...
  10. [WEB] https://publichealthpolicyjournal.com/study-329-the-big-fraud-is-finally-under-review/ [archived]
    The Study 329 scandal is not an isolated case — it's a window into how psychiatry, and much of modern medicine, became corrupted by industry control. The same tactics — ghostwritten manuscripts, selective reporting, buried suicide data — shaped the very evidence base for antidepr…
  11. [WEB] https://www.bmj.com/content/391/bmj.r2279?s=09
    A long criticised study on antidepressant use in adolescents has been flagged with an "expression of concern" by a leading academic journal after the launch of legal action.12 George Murgatroyd III, a lawyer, is suing the publishing giant Elsevier, as well as the American Academy…
  12. [WEB] https://archive.investigativereportingworkshop.org/news/whats-in-a-name-ghostly-spirits-stalk-the-medical-literature/
    14 Nov 2019 · Some internal documents have revealed the publication strategies of drugmakers and their use of ghostwriting and guest authorship to seed the ...
  13. [REDDIT] https://www.reddit.com/r/ConflictOfInterest/comments/3prvpm/study_329_conflicts_of_interest/ [archived]
    1.3K subscribers in the ConflictOfInterest community. Research, news, analysis, resources, conflicts of interest, conflicts, external, real-world…
  14. [REDDIT] https://www.reddit.com/r/MedicalWriters/comments/wko5fn/ghostwriting_ethics/ [archived]
    Any kind of contribution to the paper and respective funding sources should be disclosed/acknowledged. Any kind of ghostwriting or undisclosed support is unethical and only hurts the credibility of the profession and the research made.
  15. [REDDIT] https://www.reddit.com/r/todayilearned/comments/9xy2pj/til_of_study_329_a_pharmaceutical_study_by_the/ [archived]
    TIL of Study 329: a pharmaceutical study by the manufacturer of Paxil. It concluded that the drug was effective in treating adolescent depression. Later, it was shown that even in low risk individuals, the group taking Paxil was actually more likely to attempt suicide. : r/todayi…
  16. [REDDIT] https://www.reddit.com/r/AskAcademia/comments/lc0hhe/ethics_of_ghostwriting_peer_reviews_for_pi/ [archived]
    Ive peer reviewed with my advisor multiple times, but never Nature of Science. Not once have I received a letter from an editor. However, when the review is finished and sent to the editor, my advisor writes in an email to the editor that the review was done with the participatio…

CROSS-REFERENCE

Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias — SHARES-EVENT (OUTGOING)STUDY 329: PAROXETINE CLI…Study 329 Ghostwriting: Prior Disclosure in Review Boards or JournalsSTUDY 329 GHOSTWRITING: PRI…THIS FILESHARES-EVENT